Jean-Laurent Casanova aims to identify single-gene mutations that compromise the immunity of normally healthy individuals and lead to severe infectious disease.
The firm's assay is designed to detect the relative abundance of bacteria species in a patient's sample, allowing doctors to improve long-term inpatient care decisions.
The Nasdaq has told the firm that it is in compliance with all applicable listing standards and that its meeting with a hearings panel has been cancelled.
